Evaluation of Circulating Tumor Cells and Related Events as Prognostic Factors and Surrogate Biomarkers in Advanced NSCLC Patients Receiving First-Line Systemic Treatment
about
Current Status of CTCs as Liquid Biopsy in Lung Cancer and Future DirectionsClinical Applications of Circulating Tumor Cells in Lung Cancer Patients by CellSearch SystemMicrofluidic enrichment for the single cell analysis of circulating tumor cells.Circulating Plasma MicroRNAs As Diagnostic Markers for NSCLCCirculating tumor cells versus circulating tumor DNA in lung cancer-which one will win?CTC enumeration and characterization: moving toward personalized medicine.EGFR-Based Immunoisolation as a Recovery Target for Low-EpCAM CTC Subpopulation.Evaluation of epithelial-mesenchymal transitioned circulating tumor cells in patients with resectable gastric cancer: Relevance to therapy response.Personalized Treatment Through Detection and Monitoring of Genetic Aberrations in Single Circulating Tumor Cells.The potential diagnostic power of circulating tumor cell analysis for non-small-cell lung cancer.The role of circulating tumor cells in evaluation of prognosis and treatment response in advanced non-small-cell lung cancer.The prognostic role of circulating tumor cells in lung cancer.Circulating Tumor Cells as Cancer Biomarkers in the Clinic.A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups.Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy.Challenges and unanswered questions for the next decade of circulating tumour cell research in lung cancer.Clinical utility of circulating tumor cells in patients with non-small-cell lung cancer.Investigating CTCs in NSCLC-a reaction to the study of Jia-Wei Wan: a preliminary study on the relationship between circulating tumor cells count and clinical features in patients with non-small cell lung cancer.Molecular Profiling of Circulating Tumour Cells Identifies Notch1 as a Principal Regulator in Advanced Non-Small Cell Lung Cancer.The "liquid biopsy" in non-small cell lung cancer - not quite ready for prime time use.Prognostic significance of circulating tumor cells in non-small cell lung cancer patients undergoing chemotherapy.Critical issues in the clinical application of liquid biopsy in non-small cell lung cancer.Molecular characterization and prognostic significance of circulating tumor cells in patients with non-small cell lung cancer.Molecular characterization of circulating tumor cells in lung cancer: moving beyond enumeration.Relationship between circulating tumour cell count and prognosis following chemotherapy in patients with advanced non-small-cell lung cancer.Detection of circulating tumor cells using oHSV1-hTERT-GFP in lung cancer.[Diagnostic Value of Folate Receptor-positive Circulating Tumor Cell in Lung Cancer: A Pilot Study].Circulating MACC1 as a novel diagnostic and prognostic biomarker for nonsmall cell lung cancer.Classifying circulating tumor cells to monitor cancer progression.The role of liquid biopsy in predicting post-operative recurrence of non-small cell lung cancer.The Prognostic Role of Circulating Tumor Cells (CTCs) in Lung Cancer
P2860
Q26781333-513CFEBF-C274-4E5C-9900-F86ED195508BQ27004790-BB1CBE12-B4F8-463E-AA85-77949C5ECD81Q27340255-00101D6D-1139-4871-9FEE-017ED2AFE747Q28073562-A6C823BC-FD64-4C74-8D60-41E58D7AB001Q28077340-4F40D4D9-6CBA-47E4-BA48-8180BA842BA9Q34577724-8AB51438-0181-4164-998C-D9BFBA84E87FQ36155201-4BE59FB6-16DB-4E4E-856B-72AB4BBC1BE8Q36373625-2C118C12-3B3F-43EA-AF77-5F6041C28574Q36385825-A0151B07-E6C9-4D38-9261-945A7ED56C5EQ38632346-175195F2-835C-4268-BD39-9CBC36537250Q38746330-D8B8C25D-9934-4942-B5C1-F7DF24C8A7A6Q38874709-867A0AE0-18A5-472E-9DC5-7C5AC1D5F41AQ39339875-3FC444B3-FC73-4897-8F9E-856C29259980Q40152533-3266916C-F874-4281-A5EC-09DF8D5055B0Q40206402-F1A1A1ED-07E2-4106-A566-6B5732652A2FQ41605016-ACE5F777-880C-4058-94AF-ECB0857CDF70Q41605047-A5F04443-552B-4083-B568-FAD97E49C2F4Q41835612-AF4B3B03-6C8C-4844-B488-ADAF7AF5588EQ42084164-9984EEBA-A74A-4913-B375-AF440CDA7F4BQ42283950-C9B0A09F-B31D-4918-9390-4C61D5C7196FQ46494412-F0904CA5-204D-4EA3-9EDD-B0FAB39526CFQ47104064-444E7E9D-337F-41A1-909C-CA2C2830BAF7Q47110464-B1CAA149-1D08-47C6-B534-18E5AD6865B7Q47354317-96A865FB-6147-4316-950A-44E288231A01Q48089819-3855E214-DECD-4FA0-9346-BC094F1B2024Q48130982-72220B95-49F2-476D-B5EC-76BD888AAA17Q52942284-01FE2C90-C586-4279-83EA-51BBF8F58F64Q53652429-33CC642C-8CB9-4F4A-9D08-AA413F03D1DDQ53755908-B4F1BA92-9250-458C-960F-3DB19572F816Q55252086-9CC82D66-BA48-4EC4-962C-F83B748C77C7Q58781611-BCA7E03E-69B8-4C16-A779-9BC774492B07
P2860
Evaluation of Circulating Tumor Cells and Related Events as Prognostic Factors and Surrogate Biomarkers in Advanced NSCLC Patients Receiving First-Line Systemic Treatment
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Evaluation of Circulating Tumo ...... First-Line Systemic Treatment
@en
Evaluation of Circulating Tumo ...... First-Line Systemic Treatment.
@nl
type
label
Evaluation of Circulating Tumo ...... First-Line Systemic Treatment
@en
Evaluation of Circulating Tumo ...... First-Line Systemic Treatment.
@nl
prefLabel
Evaluation of Circulating Tumo ...... First-Line Systemic Treatment
@en
Evaluation of Circulating Tumo ...... First-Line Systemic Treatment.
@nl
P2093
P2860
P356
P1433
P1476
Evaluation of Circulating Tumo ...... First-Line Systemic Treatment
@en
P2093
Alicia Abalo
Elena Brozos
Francisca Vázquez
Francisco Barón
Laura Muinelo-Romay
Marta Alonso Nocelo
Miguel Abal
Rafael López López
Santiago Aguín
Urbano Anido
P2860
P304
P356
10.3390/CANCERS6010153
P50
P577
2014-01-21T00:00:00Z